# PULM earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/PULM) · [Earnings tab](https://www.lopjlb.com/stock/PULM?tab=earnings)

Updated: 2026-11-16T05:44:16

Quarters analyzed: 1

## Cross-quarter narrative

The sole available call from November 2014 (labeled 2015 Q2) captures Pulmatrix at an early clinical stage with its lead candidate Ruthigen. Management reported a cash position of $12.9 million, which they said extends the runway through the end of 2015. A Phase 1/2 trial had been initiated with three patients enrolled, and the company was planning a laparoscopic amendment to the protocol. Simultaneously, manufacturing preparations were underway for a pivotal trial targeted for 2015. Management tone scored 0.7, reflecting confidence in the cash position and enrollment pace, though guidance was characterized as vague and uncertainty measured at 0.5. No specific milestones, delays, or fears were flagged in the summary. With only a single data point, no temporal trends can be established; this call serves as a baseline snapshot of the company's financial cushion, early clinical activity, and forward-looking manufacturing plans as of late 2014. Subsequent calls would be needed to assess execution against the stated pivotal trial timeline and cash runway.

## Latest CallCard · Q2

Ruthigen extends cash runway to end-2015, starts Phase 1/2 trial (3 enrolled), plans laparoscopic amendment, preps manufacturing for 2015 pivotal trial.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights strong cash position ($12.9M), extended runway to end of 2015, rapid patient enroll

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2015 Q2:** Ruthigen extends cash runway to end-2015, starts Phase 1/2 trial (3 enrolled), plans laparoscopic amendment, preps manufacturing for 2015 pivotal trial.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights strong cash position ($12.9M), extended runway to end of 2015, rapid patient enroll

## Theme arcs

- **Cash runway** (improving): Extended to end-2015 with $12.9M cash
- **Clinical progress** (new): Phase 1/2 trial started, 3 patients enrolled
- **Manufacturing readiness** (new): Preparing for 2015 pivotal trial

## Guidance path

2015 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/PULM`
